News About  

Eli Lilly’s award-winning factory relies on synTQ for continuous drug manufacturing

30/10/2019 09:49:18
Download Text
ImagesClick Image for 300dpi jpg fileEli Lilly’s award-winning factory relies on synTQ for continuous drug manufacturing

October 2019, Optimal Industrial Technologies, Bristol, England. Eli Lilly and Company, a longstanding partner of Optimal Industrial Technologies has won the International Society for Pharmaceutical Engineering (ISPE)’s 2019 Facility of the Year Award (FOYA) for Process Innovation.

The accolade was recently presented in Las Vegas. The global healthcare leader was selected for its cutting-edge Continuous Drug Substance Manufacturing facility in Kinsale, Ireland which relies on synTQ software from Optimal.

ISPE’s FOYA committee recognised Eli Lilly’s Kinsale pharmaceutical plant as a clear example of what the future of active pharmaceutical ingredient (API) production will look like, according to ISPE’s report.1 The company was able to deliver a significant improvement in impurity control, process safety and environmental impacts by setting up a fully automated, continuous manufacturing facility. This applies a data-driven approach to process control and quality management.

The implementation of Process Analytical Technology (PAT) played a crucial role in the development of Eli Lilly’s intelligent ‘factory of the future’. This framework forms part of an FDA approved methodology allowing manufacturers to conduct quality testing without halting production, such as online HPLC (high-performance liquid chromatography).1 This empowers businesses to collect data that helps predict finished product attributes and how critical process parameters will affect them. As a result, it is possible to modify operating conditions during live plant operations to build quality into end products, optimising efficiency, productivity and raw material usage.

Optimal has worked closely with Eli Lilly to support the installation of synTQ, a PAT knowledge management platform that acts as a process orchestrator.1 This captures analytical and process measurements, hosts and executes multivariate quality prediction models in real-time and provides live feedback to process control equipment. Using a predictive model that can be adapted to find incremental process improvements over time also allows for continuous improvement in plant efficiency.

Martin Gadsby, Director at Optimal Industrial Technologies, comments: “We would like to congratulate Eli Lilly on the ISPE award. Our customer’s success with this project is particularly pleasing for us, as it attests to the range of benefits that synTQ can deliver in the pharmaceutical and life-science sectors. We are proud to see our solution being recognised as a key enabler to Smart Manufacturing. Our market-leading software is currently used by over half of the top ten global pharmaceutical manufacturing companies however we don’t often have the opportunity to publicise our involvement. This occasion is a welcome exception, and we look forward to helping more customers to deliver continuous process solutions.”

1 ISPE. 2019. 2019 Category Winner for Process Innovation. [ONLINE] Available at: [Accessed 30 October 2019].

Photo Caption: Eli Lilly and Company has won the International Society for Pharmaceutical Engineering (ISPE)’s 2019 Facility of the Year Award (FOYA) for Process Innovation.

About Optimal Industrial Technologies Ltd

Optimal Industrial Technologies has more than 30 years’ experience in the automation and optimisation of control and data management systems for the pharmaceutical, biotech and life science industries.

The demands being placed on manufacturers in relation to production costs, product quality and business sustainability are ever increasing; hence, the company’s primary aim is to deliver measurable improvements in all these target areas.

In addition to practical automation and system integration expertise Optimal Industrial Technologies has also developed a world leading PAT based data management software package – synTQ® which is used by over half of the world’s largest pharma companies to increase productivity and reduce time to market for OSD and biotech based drugs and therapies.

The image(s) distributed with this press release may only be used to accompany this copy, and are subject to copyright. Please contact DMA Europa if you wish to license the image for further use.

Editor Contact

DMA Europa Ltd. : Alan Hatch
Tel: +44 (0)1562 751436 Fax: +44 (0)1562 748315

Company Contact

Optimal Industrial Technologies Ltd : Martin Gadsby
Tel: +44 (0) 1454 333 222 Fax: +44 (0) 1454 322 240

  [ Back ]  
About the DMA Group Click to Read More